Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.53 |
| ▸ | FNTB | P49356 | 5/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650120 | 0.90 | FNTA (0.52) | FNTAFNTBBRD4F10 | |
| SCHEMBL650121 | 0.90 | FNTA (0.52) | FNTAFNTBBRD4F10 | |
| SCHEMBL1260557 | 0.90 | FNTA (0.52) | FNTAFNTBBRD4F10 | |
| SCHEMBL651456 | 0.90 | FNTA (0.53) | FNTAFNTBBRD4F10HTR6 | |
| SCHEMBL653070 | 0.89 | FNTA (0.48) | FNTAFNTBBRD4CYP11B1CYP11B2 | |
| SCHEMBL650256 | 0.86 | FNTA (0.50) | FNTAFNTBBRD4F10 | |
| SCHEMBL651316 | 0.85 | FNTA (0.48) | FNTAFNTBF10 | |
| SCHEMBL651273 | 0.85 | FNTA (0.49) | FNTAFNTBHTR6 | |
| SCHEMBL651315 | 0.85 | FNTA (0.49) | FNTAFNTBHTR6 | |
| SCHEMBL651274 | 0.85 | FNTA (0.49) | FNTAFNTBHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | claimed |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | claimed |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | claimed |
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | FNTA 1368/4885FNTB 2071/4885BRD4 87/4885 |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | FNTA 1368/4885FNTB 2071/4885BRD4 87/4885 |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | FNTA 1368/4885FNTB 2071/4885BRD4 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.